November 19th, 2018
Unlike the purported benefit of its male enhancement supplement, the marketer of Androzene failed to rise to the occasion when faced with a recent inquiry into its advertising claims.
The National Advertising Division (NAD) said claims such as the one indicated above — which appeared on the Androzene website as recently as September, according to the Internet Archive — convey the message that Androzene provides male consumers “substantial, if not complete, relief from erectile dysfunction,” or ED.
In response to a request for substantiation, rather than provide NAD with evidence of product testing in support of its claims, Androzene offered the self-regulatory body a medical expert’s report on studies of two ingredients in the supplement: yohimbine and caffeine.
NAD was not impressed. According to a release:
NAD noted several flaws in the ingredient studies including, but not limited to, the fact that most of the studies tested […] different doses of yohimbine and caffeine than in the Androzene proprietary blend and others tested ingredients not found in the product.
NAD noted that the one study that tested an ingredient in the amount in which it is found in Androzene “showed no statistically significant differences between yohimbine and placebo groups with respect to improvement in erectile function.”
It recommended that Androzene discontinue a minimum of seven health-related performance claims. Androzene said it would comply with the decision.
Find more of our coverage on sexual enhancements here.
The National Advertising Division, or NAD, is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus. NAD asks advertisers to substantiate or change their claims in advertisements. As part of a voluntary system of self-regulation, however, its recommendations can be ignored by the offending advertisers. In those instances, NAD refers the offender to federal consumer protection agencies.